Olive Fruit Extract.

Hydroxytyrosol and the olive biphenols act in the aqueous phase while tocopherol works inside the lipid membrane, so the two cover different compartments of the same lipid peroxidation chain. Olive phenolics also help regenerate the oxidised tocopheroxyl radical.

Ascorbate reduces phenoxyl radicals formed when olive polyphenols and tocopherol donate an electron, returning them to their active form. That recycling is why phenolic antioxidants are routinely paired with vitamin C.

Long-chain omega-3 fatty acids are highly unsaturated and prone to peroxidation, and olive polyphenols slow that chain reaction in the lipid fraction. Pairing them keeps the fatty acids intact in the product and in circulating lipoproteins.

Olive leaf carries oleuropein and olive fruit carries oleuropein plus its hydrolysis product hydroxytyrosol. They contribute to the same secoiridoid pool, so the two should be counted together rather than as separate actives.

Catechol-type polyphenols such as hydroxytyrosol chelate non-heme iron in the gut and lower its uptake. Separating the two by a couple of hours keeps the mineral available.

Olive fruit phenolics are ortho-diphenols that donate a hydrogen atom to lipid peroxyl radicals in the aqueous and interfacial layers, while tocopherols do the same work inside the lipid core. The two therefore act at different positions in the same emulsion rather than duplicating each other. In an oil-based softgel this pairing is also a formulation decision, because tocopherol slows oxidation of the carrier oil itself. Marker chemistry, not an outcome.

Reduced coenzyme Q10 and olive phenolics both intercept lipid radicals, and ubiquinol can be regenerated by other reducing species present in the same matrix. Co-formulation is common in oil-filled capsules where an added phenolic slows oxidation of the vehicle. What has been measured for either compound alone is oxidation markers rather than a clinical endpoint.

Astaxanthin spans the membrane bilayer while hydroxytyrosol and tyrosol sit at the polar interface, so the two occupy different positions in the same oxidisable structure. Formulators pair them for that reason in oil-based antioxidant blends. No combination trial is cited here and the reasoning is chemical.

Hydroxytyrosol and catechins are both heavily sulfated and glucuronidated by intestinal and hepatic SULT and UGT enzymes on first pass. Taken together in quantity they draw on the same conjugating capacity, which can shift how much of either circulates unconjugated. The direction of that shift depends on dose and is a pharmacokinetic point, not an efficacy claim.

Resveratrol shares the sulfation and glucuronidation route that limits free hydroxytyrosol in plasma, so the two are competitors for clearance capacity as much as partners. They differ in where they distribute, resveratrol being more lipophilic. Any combined effect described here is mechanistic reasoning about exposure.

Dihydrolipoic acid reduces oxidised forms of several antioxidants, and phenolic radicals formed after hydrogen donation are chemically available to such reductants. That makes the pair complementary in a redox network sense. The claim is about chemistry in solution, not a measured human outcome.

The phenolic fraction of olive fruit extract is water soluble, but the same extracts carry lipophilic components including maslinic and oleanolic acid and squalene, which need dietary or formulated fat to be solubilised into mixed micelles. A medium-chain triglyceride vehicle supplies that fat in a small volume. This applies to the fat-soluble fraction only and says nothing about the hydroxytyrosol content.

Phospholipids are used to disperse polyphenol extracts, keeping them in a fine emulsion rather than settling or aggregating in an oil fill. That is a delivery and stability decision made at the bench. Whether it changes what reaches the blood depends on the specific formulation and is not established for this extract.

Catechol groups such as those on hydroxytyrosol bind divalent transition metals, copper included, which is part of why they slow metal-catalysed lipid oxidation. In the gut lumen that same binding can reduce the fraction of a copper salt available for uptake if both are taken at once. Separating the two by a couple of hours removes the question. The chelation chemistry is settled; the size of any effect on copper status is not.

Polyphenol-rich extracts bind divalent cations and can lower the soluble fraction of a zinc salt taken in the same dose. This is the same chemistry that makes tea reduce non-heme iron uptake. Spacing the doses is the ordinary handling. The competition is established; the magnitude for olive extract specifically has not been quantified here.

N-acetylcysteine feeds cysteine into glutathione synthesis, giving a thiol arm to a system where olive phenolics act by direct hydrogen donation. The two work by different chemistry on the same problem. This is mechanism only and neither claim here is an outcome.

Piperine inhibits glucuronidation in the gut wall and liver, which is the main route that clears hydroxytyrosol and its relatives. Co-formulation is therefore a plausible way to raise the unconjugated fraction of a phenolic dose. The same inhibition applies to unrelated compounds a person may be taking, so it is a general pharmacokinetic lever rather than a targeted one.